BioMedomics Receives CE Mark Approval for alpha-Thal SCAN(TM)
BioMedomics is happy to announce that we have received CE Mark Approval for our innovative point-of-care test, alpha-Thal SCAN.
alpha-Thal SCAN(TM) is a qualitative point-of-care lateral flow immunoassay which is used to diagnose Alpha Thalassemia. The test indicates the presence of alpha-thalassemia with Southeast Asian cis-deletion (alpha-thalassemia trait), and HbH disease.
alpha-Thalassemia (AT) is a blood disorder that reduces the production of hemoglobin. It affects 300,000 - 400,000 newborns per year primarily in Southeast Asia, India and the Middle East. People with AT trait are often asymptomatic, but are highly likely to give birth to children with more severe forms of AT, which could lead to early deaths. As with sickle cell disease, this condition is significantly underdiagnosed due to the requirement for complex and expensive central lab equipment.
However, unlike other alpha-thalassemia tests which must be done in a lab setting with professional technicians, alpha-Thal SCAN kit requires no additional equipment, and takes less than 5 minutes to run, dramatically reducing overall cost and turnaround time.
If you would like to learn more about this product, please follow this link: thal-scan.com. Or contact us at firstname.lastname@example.org. Our staff is readily available to answer your questions.
For a complete demonstration of how alpha-Thal SCAN works, please watch this video: